The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial.

Papadaki T, Tsilimbaris M, Thermos K, Karavellas M, Samonakis D, Papapdakis A, Linardakis M, Kouromalis E, Pallikaris I

Retina (Philadelphia, Pa.)1 Dec 2003Cited by 5 (Europe PMC)

PMID14707831DOI10.1097/00006982-200312000-00010PepBankPUB-14707831

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with CNV, visual acuity remained stable from baseline to 6 months during lanreotide treatment.
In plain wordsIn patients with CNV, vision remained stable during six months of lanreotide treatment.
Peptide
Lanreotide
Outcome
No significant changeVisual acuity during treatment
Study
n = 10
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
From baseline to 6 months, the mean visual acuity and surface area of hyperfluorescence remained stable in the study group, while the intensity of hyperfluorescence decreased.
3 context sentences(design, population, supporting numbers)
Summary · context
Twenty eyes of 20 patients with CNV were included in the study.
Summary · context
Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).
Summary · context
Patients received one intramuscular injection of lanreotide or placebo every 15 days for a total of 6 months.
Report a problemFND-1470783101
02HumanNon-randomized trialEfficacy outcome
In patients with CNV, hyperfluorescence surface area remained stable during lanreotide treatment.
In plain wordsIn patients with CNV, the fluorescent area remained stable during lanreotide treatment.
Peptide
Lanreotide
Outcome
No significant changeHyperfluorescence surface area during treatment
Study
n = 10
Outcome group
Retinal imaging · Eye
Studied dose
Dose not stated · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
From baseline to 6 months, the mean visual acuity and surface area of hyperfluorescence remained stable in the study group, while the intensity of hyperfluorescence decreased.
3 context sentences(design, population, supporting numbers)
Summary · context
Twenty eyes of 20 patients with CNV were included in the study.
Summary · context
Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).
Summary · context
Patients received one intramuscular injection of lanreotide or placebo every 15 days for a total of 6 months.
Report a problemFND-1470783102
03HumanNon-randomized trialEfficacy outcome
In patients with CNV, hyperfluorescence intensity decreased during lanreotide treatment without a significant difference from baseline.
In plain wordsIn patients with CNV, fluorescence intensity decreased during lanreotide treatment, but the difference from baseline was not significant.
Peptide
Lanreotide
Outcome
No significant changeHyperfluorescence intensity during treatment
Study
n = 10
Outcome group
Retinal imaging · Eye
Studied dose
Dose not stated · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
From baseline to 6 months, the mean visual acuity and surface area of hyperfluorescence remained stable in the study group, while the intensity of hyperfluorescence decreased.
4 context sentences(design, population, supporting numbers)
Summary · context
Statistical analysis, however, failed to reveal any significant difference from baseline.
Summary · context
Twenty eyes of 20 patients with CNV were included in the study.
Summary · context
Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).
Summary · context
Patients received one intramuscular injection of lanreotide or placebo every 15 days for a total of 6 months.
Report a problemFND-1470783103
04HumanNon-randomized trialEfficacy outcome
In patients with CNV, visual acuity deteriorated after lanreotide discontinuation, without a significant difference from baseline.
In plain wordsIn patients with CNV, vision worsened after lanreotide stopped, but the difference from baseline was not significant.
Peptide
Lanreotide
Outcome
No significant changeVisual acuity after discontinuation
Study
n = 10
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
After discontinuation of treatment, deterioration of all three parameters was noted in the study group.
4 context sentences(design, population, supporting numbers)
Summary · context
Statistical analysis, however, failed to reveal any significant difference from baseline.
Summary · context
Twenty eyes of 20 patients with CNV were included in the study.
Summary · context
Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).
Summary · context
Patients received one intramuscular injection of lanreotide or placebo every 15 days for a total of 6 months.
Report a problemFND-1470783104
05HumanNon-randomized trialEfficacy outcome
In patients with CNV, hyperfluorescence surface area deteriorated after lanreotide discontinuation, without a significant difference from baseline.
In plain wordsIn patients with CNV, the fluorescent area worsened after lanreotide stopped, without a significant difference from baseline.
Peptide
Lanreotide
Outcome
No significant changeHyperfluorescence surface area after discontinuation
Study
n = 10
Outcome group
Retinal imaging · Eye
Studied dose
Dose not stated · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
After discontinuation of treatment, deterioration of all three parameters was noted in the study group.
4 context sentences(design, population, supporting numbers)
Summary · context
Statistical analysis, however, failed to reveal any significant difference from baseline.
Summary · context
Twenty eyes of 20 patients with CNV were included in the study.
Summary · context
Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).
Summary · context
Patients received one intramuscular injection of lanreotide or placebo every 15 days for a total of 6 months.
Report a problemFND-1470783105
06HumanNon-randomized trialEfficacy outcome
In patients with CNV, hyperfluorescence intensity deteriorated after lanreotide discontinuation, without a significant difference from baseline.
In plain wordsIn patients with CNV, fluorescence intensity worsened after lanreotide stopped, without a significant difference from baseline.
Peptide
Lanreotide
Outcome
No significant changeHyperfluorescence intensity after discontinuation
Study
n = 10
Outcome group
Retinal imaging · Eye
Studied dose
Dose not stated · intramuscular · 6 monthsAs given in this study (human).
Source sentences
Summary
After discontinuation of treatment, deterioration of all three parameters was noted in the study group.
4 context sentences(design, population, supporting numbers)
Summary · context
Statistical analysis, however, failed to reveal any significant difference from baseline.
Summary · context
Twenty eyes of 20 patients with CNV were included in the study.
Summary · context
Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).
Summary · context
Patients received one intramuscular injection of lanreotide or placebo every 15 days for a total of 6 months.
Report a problemFND-1470783106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.